Elena Anderson, Marketing Manager |
Group
The International Market Analysis Research and Consulting Group is a leading adviser on management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, chemicals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
IMARC’s tailored approach combines unfathomable insight into the dynamics of companies and markets with close cooperation at all levels of the client organization. This ensures that our clients achieve unmatchable competitive advantage, build more proficient organizations, and secure lasting results.
The latest report by IMARC, titled “ OnychomycosisTreatmentMarket:GlobalIndustryTrends,Share,Size,Growth,OpportunityandFor ecast2023-2028
” finds that the global onychomycosis treatment market reached a value of US$ 3.1 Billion in 2022.
Onychomycosis is a fungal infection that occurs in the fingernails and toenails, resulting in discomfort, discoloration, chronic pain, and disfigurement. It is a common nail infection in patients with athlete’s feet and is caused by various organisms, such as dermatophytes, yeasts, and non-dermatophyte molds. It is usually diagnosed through oxygen and hydrogen (KOH) examination, potassium, culture, and histopathological examinations of nail clippings and nail biopsies and is treated through laser therapy, drugs, and photodynamic therapies.
Request Free Sample Report: https://www.imarcgroup.com/onychomycosis-treatment-market/requestsample
The market is primarily driven by the rising prevalence of chronic medical ailments, such as onychomycosis, human immunodeficiency virus (HIV), diabetes, and peripheral artery disease (PAD) among the masses. In addition, the development of water-soluble antifungal treatment solutions that can be administered orally and aid in preventing secondary bacterial infections and the growth of fungus represents another major growth-inducing factor. Besides this, onychomycosis is highly prevalent among millennials and adults due to the increased exposure to public swimming pools and utilization of tight, contaminated, or soiled clothes, shoes, and socks.
This, coupled with the rising popularity of topical nail lacquers and ointments to maintain nail hygiene, is contributing to the market growth. Moreover, the developing healthcare infrastructure across the globe is also creating a favorable market outlook. Looking forward, IMARC Group expects the market to reach US$ 4.3 Billion by 2028, exhibiting a CAGR of 5.37% during the forecast (2023-2028).
Looking forward, the market value is projected to reach a strong growth during the forecast period (2023-2028).
MarketSummary:
BreakupbyDiseaseType:
• Distal Subungual Onychomycosis
• Proximal Subungual Onychomycosis
• White Superficial Onychomycosis
• Candidal Onychomycosis
• Others
BreakupbyTreatmentType:
• Laser Therapy
• Photodynamic Therapy
• Drug Treatment
BreakupbyDrugClass:
• Allylamine
• Azole
• Griseofulvin
• Others
BreakupbyDistributionChannel:
• Hospitals and Clinics
• Online Stores
• Retail Pharmacies
• Others
BreakupbyRegion:
• North America
• United States
• Canada
• Asia-Pacific
• China
• Japan
• India
• South Korea
• Australia
• Indonesia
• Others
• Europe
• Germany
• France
• United Kingdom
• Italy
• Spain
• Russia
• Others
• Latin America
• Brazil
• Mexico
• Others
• Middle East and Africa
CompetitiveLandscapewithKeyPlayers:
• Bausch Health Companies Inc
• Cipla Limited
• Dr. Reddy's Laboratories
• Galderma SA
• GlaxoSmithKline PLC
• Kaken Pharmaceutical Co. Ltd
• Lumenis Ltd
• Moberg Pharma AB
• Novartis AG
• Pfizer Inc.
• The OTC Lab B.V
ViewFullReportwithTOC&ListofFigure:
https://www.imarcgroup.com/onychomycosis-treatment-market
© 2019 IMARC All Rights Reserved
This Publication and all it’s contents unless otherwise mentioned are copyrighted in the name of International Market Analysis Research and Consulting (IMARC). No part of this publication may be reproduced, repackaged, redistributed or resold in whole or in any part. The publication may also not be used in any form or by and means graphic electronic or mechanical, including photocopying, recording, taping or by information storage or retrieval, or by any other form, without the express consent of International Market Analysis Research and Consulting (IMARC).
Disclaimer: All contents and data of this publication, including forecasts, data analysis and opinion have been based on information and sources believed to be accurate and reliable at the time of publishing. International Market Analysis Research and Consulting makes no representation of warranty of any kind as to the accuracy or completeness of any Information provided. IMARC accepts no liability whatsoever for any loss or damage resulting from opinion, errors or inaccuracies if any found this publication.
IMARC, IMARC Group and Global Therapy Insight Series are registered trademarks of International Market Analysis Research and Consulting. All other trademarks used in this publication are registered trademarks of their respective companies.
